Case Report of Two Cases of Fever, Rash, and Organ Involvement during the Treatment of Leprosy

Hong Liu1,2,3,4, Chuan Wang1,3, Tongsheng Chu1,3, Parimi Leela Rani2, Debao Yu5, Xi’an Fu1,3, Mingfei Chen1,3, Shumin Chen1,3, Furen Zhang1,2,3,4,5

1 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China, 2 Shandong Provincial Hospital for Skin Diseases, Shandong University, Jinan, Shandong, China, 3 Shandong Provincial Key Lab for Dermatovenereology, Jinan, Shandong, China, 4 Shandong Provincial Medical Center for Dermatovenereology, Jinan, Shandong, China, 5 Jinan Institute of Dermatology, Jinan, Shandong, China

Presentation of Cases

1

The first patient was a 65-year-old man whose chief complaint was high fever accompanied by generalized rash for two days. The patient first appeared in the clinics of Shandong Provincial Institute of Dermatology and Venereology with a two-year history of rash (erythema and patches) on his legs and hands without subjective syndromes (Figure 1). Besides the skin, ulnar nerves were found to be thick. Acid-fast bacilli (+) were found in the tissue smear and histopathological examinations. The diagnosis of borderline tuberculoid (BT) leprosy was confirmed by real-time PCR for Mycobacterium leprae gene encoding antigen 85B in the skin samples. Then, multidrug therapy (MDT) (for paucibacillary leprosy: dapsone [DDS] and rifampicin) was given accordingly. She was readmitted 21 days after she underwent MDT, with presentation of fever and generalized puritic rash. Upon admission, her temperature was 39.2°C and pruritic intensive papular exanthematous rash on the trunk and extremities were observed (Figure 3). The other system examinations were normal.

The laboratory investigation revealed that hemoglobin was at 74 g/L (RV≤21 umol/L). Enlargement of inguinal lymph nodes could be observed under high frequency ultrasound.

The second patient was a 39-year-old woman who was from Yunnan province, an epidemic area of leprosy in China. Her chief complaint was also fever and extensive rash on her trunk for one day. Her first admission was due to the painful ulceration on her feet with a three-year history. Also, ulnar nerves were affected. The examinations of smear test and pathology showed vast acid-fast bacilli (+), and real-time PCR for Mycobacterium leprae gene revealed the specificity of bacilli, which supported the diagnosis of lepromatous leprosy. MDT for multibacillary leprosy (DDS, clofazimine, and rifampicin) was given accordingly. She was readmitted 21 days after she underwent MDT, with presentation of fever and generalized pruritic rash. Upon admission, her temperature was 39.2°C and pruritic intensive papular exanthematous rash on the trunk and extremities were observed (Figure 3). The other system examinations were normal.

The laboratory investigation revealed that hemoglobin was at 74 g/L (RV≤21 umol/L). Enlargement of inguinal lymph nodes could be observed under high frequency ultrasound.

What Is the Diagnosis and the Differential Diagnosis?

All the symptoms of the two patients were firstly suspected to be a drug-induced hypersensitivity syndrome (DIHS) caused by MDT, especially DDS. Of course, rifampicin was also reported to be one of sensitizing drugs of DIHS [1–4]. We could not exclude the diagnosis of leprosy reactions totally at this phase.

While treating leprosy patients, physicians should be well familiarized with conditions such as DIHS and leprosy reactions. Due to the distinct managements, timely differentiation of the two diseases is important. The former usually develops within two months after drug introduction and presents clinically as an extensive rash, accompanied by fever and the involvement of organs, such as lymphadenopathy, hepatitis, hematologic abnormalities and so on. Leprosy reactions include two types: Type 1 reaction (T1R), or reversal reaction, and type 2 reaction (T2R), or erythema nodosum leprosum (ENL). T1R and T2R may occur separately or together, or one after the other, and may appear before, during, or after the treatment of leprosy. In T1R, skin involvement (new lesions may suddenly appear and/or old lesions become red and swollen) frequently accompanies nerve involvement. T2R is a generalized disease, which could affect skin, nerves, and other organs such as joints and lymph nodes, often accompanied by fever and elevated WBC count. Sometimes it is...
difficult to distinguish DIHS from T1R and T2R, especially when the symptoms are not complete in these two diseases.

For the first patient, with an elevated WBC of $16.34 \times 10^9/L$ and high fever of $39.6^\circ C$, T2R was not taken into account because T2R typically occurs in the patients who undergo treatment for lepromatous or borderline lepromatous forms of leprosy, not in BT patients. Also, in these two patients there were no complaints of nerve pain and no significant signs of nerve damage were observed under ultrasound. High-grade fever and rash were the first signs after drug intake. All the above findings inclined towards the diagnosis of DIHS. There were more reported cases of DDS being the offending agent in DIHS rather than rifampicin. So, we speculated that DDS induced this DIHS.

What Led to the Final Diagnosis of Dapsone Induced Hypersensitivity Syndrome?

To find more evidence for diagnosis and to decide whether DDS or rifampicin induced the hypersensitivity reactions, we performed an analysis using HLA-B*13:01 test in the two patients. HLA-B*13:01 has been identified as a risk predictor of DDS-
induced hypersensitivity syndrome (DDS syndrome) with 85.5% of sensitivity and 85.7% of specificity [5]. The presence or absence of the HLA-B*13:01 risk allele was determined using sequence-specific polymerase-chain-reaction assay primers (PCR-SSP), and the electrophoresis results of the two cases showed both of the patients carried one risk allele of HLA-B*13:01, which supported the diagnosis of DDS syndrome.

To be on the safe side, MDT was stopped immediately and corticosteroids were given orally (prednisolone 1 mg/kg/d). Their clinical condition improved quickly, and laboratory test results returned to normal levels within about one month (Figure 4 and 5). Then the steroids were slowly tapered and stopped over a period of nearly seven weeks.

After that, DDS was removed from MDT. For the first patient, rifampicin and clofazimine as an alternative drug combination were used for leprosy treatment, and no recurrence of DDS syndrome was observed during the follow-up of six months. For the second patient, also, rifampicin and clofazimine were used in treatment. However, she suffered another attack of fever and rash, as she mistakenly took one pill of DDS. After being treated with prednisolone again for one month, all the clinical symptoms disappeared and no recurrence of DDS syndrome was observed in the follow-up of three months.

Our diagnosis of DDS syndrome was based on the combination of symptoms, the two patients’ medical history, and the results of HLA-B*13:01 test. The two patients remain under supervised treatment for leprosy, with good outcome.

What Is the Difference between Complete DDS Syndrome and the Incomplete Form?

The first patient presented the full symptoms, including fever, lymphadenopathy, generalized rash, and abnormal liver function after DDS intake, which met the criteria of complete DDS syndrome proposed by Richardus and Smith [6]. But not all those features are necessarily needed to
Figure 4. Clinical manifestations of the first patient after the treatment. The rash of DDS syndrome disappeared and only original lesions could be found on his leg.
doi:10.1371/journal.pntd.0003130.g004

Figure 5. Clinical manifestations of the second patient after the treatment. The rash disappeared totally.
doi:10.1371/journal.pntd.0003130.g005
Key Learning Points

- This case report is a useful reminder that clinicians should be aware of the possible fatal adverse effects of dapsone (DDS).
- The HLA-B*13:01 test is useful to distinguish DDS syndrome from leprosy reactions.
- The HLA-B*13:01 test before treatment will be useful to prevent DDS syndrome.

References

1. Liu BA, Knowles SR, Cohen LB, Werb MR, Shear NH (1997) Pancreatic insufficiency due to antituberculous therapy. Ann Pharmacother 31: 724–726.
2. Miasnikov VH (1993) Acute hepatorenal failure occurring after taking rifampicin. Lik Sprava (7): 124–126.
3. Besse J, Vandevenne A, Petitjean R, Burghard G (1977) "Immuno-allergic" complications of rifampicin therapy. Poumon Coeur 33: 107–115.
4. Martinez E1, Collazos J, Mayo J (1999) Hypersensitivity reactions to rifampicin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 78: 361–369.
5. Zhang FR, Liu H, Irwanto A, Fu XA, Li Y, et al. (2013) HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 369: 1620–1628. doi:10.1056/NEJMoa1213096.
6. Richardus JH, Smith TC (1989) Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Lepr Rev 60: 267–273.
7. Leta GC, Simas MEPAS, Oliveira MLW, Gomes MK (2003) Síndrome de hipersensibilidade à dapsone: revisão sistemática dos critérios diagnósticos. Hansenol Int 28: 79–84.
8. Zhu YI, Stiller MJ (2001) Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 45: 420–434.
9. Rao PN, Lakshmi TS (2001) Increase in the incidence of dapsone hypersensitivity syndrome—an appraisal. Lepr Rev 72: 57–62.
10. Leslie KS, Gaffney K, Ross CN, Ridley S, Barker TH, et al. (2003) A near fatal case of the dapsone hypersensitivity syndrome in a patient with urticarial vasculitis. Clin Exp Dermatol 28: 496–498.
11. Lorenz M, Wozel G, Schmitt J (2012) Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 92: 194–199.
12. Chung WH, Hung SI, Hong HS, Ish MS, Yang LC, et al. (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428: 468.
13. Chen P, Liu J, Lu CS, et al. (2013) Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364: 1126–1133.